FDA Approves Zydelig for Three Types of Blood Cancer
But label warns drug may be toxic to liver
WEDNESDAY, July 23, 2014 (HealthDay News) -- Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma, the FDA said Wednesday in a news release.
The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said.
The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, hyperglycemia, elevated liver enzymes, hypertriglyceridemia, and colitis. Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash.
Zydelig is marketed by Gilead Sciences, based in Foster City, Calif.